A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA

BACKGROUND: Rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is the current standard therapy for diffuse large B cell lymphoma (DLBCL). Obinutuzumab (G), a glycoengineered, type II anti-CD20 monoclonal antibody, has shown activity and an acceptable safety profile...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hematol Oncol
Main Authors: Sehn, Laurie H., Martelli, Maurizio, Trněný, Marek, Liu, Wenxin, Bolen, Christopher R., Knapp, Andrea, Sahin, Deniz, Sellam, Gila, Vitolo, Umberto
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Rapid Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7276080/
https://ncbi.nlm.nih.gov/pubmed/32505213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00900-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados